DCLK1 may be a predictive biomarker of CCA prognosis, and targeting the PI3K/AKT/mTOR pathway may be a potential strategy to improve prognosis in CCA patients with higher DCLK1 expression. Here, MTOR is linked to cholangiocarcinoma.